Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory. Malik, L., Chua, Y., J., Butt, N., S., & Yip, D. Asia-Pacific Journal of Clinical Oncology, 12(1):e133-e140, American Society of Clinical Oncology, 2016.
Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory [pdf]Paper  abstract   bibtex   
Aims: Retrospective review of neuroendocrine tumors (NETs) treated within the Australian Capital Territory to describe the local epidemiology and assess prognostic clinicopathological factors. Methods: Patients with histologically proven non-pulmonary low to intermediate grade NETs were identified from our hospital clinical database. Data were analyzed according to epidemiological, clinical and histopathological characteristics. Results: Of the 107 included patients, the most common primary tumor site was jejunum/ileum (32%), followed by rectum (22%) and pancreas (11.2%). In total, 32% had distant metastases at presentation, most commonly in the liver. Most patients were symptomatic at diagnosis, while 22.4% of cases were found incidentally. Second malignancies, in particular of gastrointestinal origin, were diagnosed in 33.6%. Surgical debulking was the most common treatment (59.8%) while 18% had multimodality therapy. With a median follow-up of 25 months from diagnosis, about 78% of patients are still alive. Median time to first relapse was 15 months and the 5-year survival rate was 80% for NETs of jejunum/ileum. Univariate survival analysis revealed tumor location, high Ki67 index, raised plasma chromogranin A, and urine 5-hydroxyindoleacetic acid upon diagnosis to be associated with shorter 5-year survival. Conclusion: The epidemiologic characteristics and long-term outcome in our series are comparable to other reported studies. This analysis presents some important prognostic factors which could be used for risk stratification in patients with NETs.
@article{
 title = {Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory},
 type = {article},
 year = {2016},
 identifiers = {[object Object]},
 keywords = {Chromogranin A,Epidemiology,Neuroendocrine tumors,Prognostic factors,Survival},
 pages = {e133-e140},
 volume = {12},
 publisher = {American Society of Clinical Oncology},
 id = {1f6d3765-3362-359e-8191-f91604aecdfd},
 created = {2020-09-18T15:01:45.986Z},
 file_attached = {true},
 profile_id = {49efd9d1-b84a-3562-b8db-36e64ac7ba81},
 last_modified = {2021-03-11T17:24:52.084Z},
 read = {false},
 starred = {false},
 authored = {true},
 confirmed = {true},
 hidden = {false},
 citation_key = {malik2013single},
 source_type = {article},
 folder_uuids = {4cfcf1ef-e8a1-481b-9768-92f271f79e14,61cd76d5-8771-4789-bd8b-c373e7bef009},
 private_publication = {false},
 abstract = {Aims: Retrospective review of neuroendocrine tumors (NETs) treated within the Australian Capital Territory to describe the local epidemiology and assess prognostic clinicopathological factors. Methods: Patients with histologically proven non-pulmonary low to intermediate grade NETs were identified from our hospital clinical database. Data were analyzed according to epidemiological, clinical and histopathological characteristics. Results: Of the 107 included patients, the most common primary tumor site was jejunum/ileum (32%), followed by rectum (22%) and pancreas (11.2%). In total, 32% had distant metastases at presentation, most commonly in the liver. Most patients were symptomatic at diagnosis, while 22.4% of cases were found incidentally. Second malignancies, in particular of gastrointestinal origin, were diagnosed in 33.6%. Surgical debulking was the most common treatment (59.8%) while 18% had multimodality therapy. With a median follow-up of 25 months from diagnosis, about 78% of patients are still alive. Median time to first relapse was 15 months and the 5-year survival rate was 80% for NETs of jejunum/ileum. Univariate survival analysis revealed tumor location, high Ki67 index, raised plasma chromogranin A, and urine 5-hydroxyindoleacetic acid upon diagnosis to be associated with shorter 5-year survival. Conclusion: The epidemiologic characteristics and long-term outcome in our series are comparable to other reported studies. This analysis presents some important prognostic factors which could be used for risk stratification in patients with NETs.},
 bibtype = {article},
 author = {Malik, Laeeq and Chua, Yu Jo and Butt, Nadeem S. and Yip, Desmond},
 journal = {Asia-Pacific Journal of Clinical Oncology},
 number = {1}
}
Downloads: 0